Replies to post #249 on Amplia Therapeutics Ltd. (INNMF)

[Smilin_B]

ASX RELEASE 4 May 2018
Innate Immunotherapeutics completes acquisition of Amplia Therapeutics
and new Board appointments
Innate Immunotherapeutics Limited (ASX Code: IIL) is pleased to announce that it has today
completed the acquisition of privately owned Melbourne-based biopharmaceutical company Amplia
Therapeutics Pty Ltd (Amplia). As a result of the transaction, the Company will accelerate the
development of Amplia's Focal Adhesion Kinase (FAK) inhibiting drug candidates for application in
immuno-oncology and other indications.
The FAKi candidates AMP886 and AMP945 represent highly attractive compounds for clinical
development possessing excellent potency and drug-like properties, biological selectivity,
bioavailability and manufacturing scale-up potential. Innate has acquired all the shares of Amplia in
exchange for 18,460,308 new ordinary shares issued today by Innate. Following this weeks 10 for 1
share consolidation and the issue of new shares to the Amplia shareholders, Innate now has
41,023,303 shares on issue.
The completion of the Amplia transaction has also occasioned a change in the composition of the
Innate Board. Chris Collins, the Company's previous largest shareholder and director since early
2006, has today retired as a director. "Chris has been a stalwart supporter of Innate for over ten
years and the Company would never have been able to progress the clinical development of our
previous drug candidates without his encouragement and backing. We owe him a very big vote of
thanks." said CEO Simon Wilkinson.
The Company also records its sincere thanks to Elizabeth Hopkins, Andrew Sneddon, and Chairman
Michael Quinn, all of whom are today stepping down from the Board. "Innate's shareholders and our
many other stakeholders have been very well served by this group of committed and very
professional independent directors" said Mr Wilkinson.
Joining the Board’s remaining members Robert Peach and Simon Wilkinson from today are Andrew
Cooke, Chris Behrenbruch, Chris Burns, and Warwick Tong. Mr Cooke, the Company's Secretary since
late 2013, has extensive experience in law, corporate finance, governance and compliance. Mr
Cooke will chair the Company's Audit Committee. Messrs Behrenbruch, Burns, and Tong were
formally directors of Amplia and have a deep knowledge of the FAK assets now owned by Innate.
Each also has over 20 years hands-on experience in the pharmaceutical and biotechnology industry.